Systemic corticosteroids for the treatment of COVID19: Equityrelated analyses and update on evidence, Cochrane Library

Authors ' conclusions Systemic corticosteroids probably slightly reduce all ‐cause mortality up to 30 days in people hospitalised because of symptomatic COVID‐19, while the evidence is very uncertain about the effect on all‐cause mortality up to 120 days. For younger people (under 70 years of age) there was a potential advantage, as well as for Black, Asian, or people of a minority ethnic group; further subgroup analyses showed no relevant effects. Evidence related to the most effective type, dose, or timing of systemic corticosteroids remains immature. Currently, there is no evidence on asymptomatic or mild disease (non‐hospitalised participants). Due to the low to very low certainty of the current evidence, we cannot assess safety adequately to rule out harmful effects of the treatment, therefore there is an urgent need for good‐quality safety data. Findings of equity‐related subgroup analyses should be interpreted with caution because of their exp lorative nature, low precision, and missing data. We identified 42 ongoing and 23 completed studies lacking published results or relevant information on the study design, suggesting there may be possible changes of the effect estimates and certainty of the evidence in the future.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news